Clinical Trials · NCT05652205

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

CompletedPhase 3Linaclotide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
AbbVie
Enrollment
123
Start date
Dec 2022
Locations
48 sites, 4 countries
Primary endpoint
Change From Baseline in 12-week Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) Observed by the Primary Caregiver During the Double-blind Study Intervention Period
View Linaclotide compound reference